Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 18/20 | 0.53 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.36 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.36 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.36 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4835460 | 0.99 | TACR1 (0.52) | TACR1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL5278283 | 0.88 | TACR1 (0.41) | TACR1SLC6A4 | |
| SCHEMBL5250085 | 0.86 | TACR1 (0.55) | TACR1SLC6A4KCNH2 | |
| SCHEMBL5248333 | 0.85 | TACR1 (0.50) | TACR1SLC6A4KCNH2 | |
| SCHEMBL5251374 | 0.85 | TACR1 (0.50) | TACR1SLC6A4KCNH2 | |
| SCHEMBL5246897 | 0.85 | TACR1 (0.53) | TACR1SLC6A4KCNH2 | |
| Hydrochloric Acid SCHEMBL4836180 | 0.85 | TACR1 (0.54) | TACR1SLC6A4KCNH2 | |
| Hydrochloric Acid SCHEMBL4827354 | 0.84 | TACR1 (0.49) | TACR1SLC6A4KCNH2 | |
| Hydrochloric Acid SCHEMBL4830215 | 0.84 | TACR1 (0.52) | TACR1SLC6A4KCNH2 | |
| Hydrochloric Acid SCHEMBL4826718 | 0.84 | TACR1 (0.49) | TACR1SLC6A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442692-B2 | Indanyl-piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2008-10-28 | — | — | US | claimed |
| EP-1707564-B1 | Indanyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2007-09-12 | — | — | EP | claimed |
| US-20060223830-A1 | Indanyl-piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2006-10-05 | — | — | US | claimed |
| WO-2006103342-A2 | INDANYL-PIPERAZINE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2006-10-05 | — | — | WO | claimed |
| EP-1707564-A2 | Indanyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2006-10-04 | — | — | EP | claimed |
| US-7442692-B2 | Indanyl-piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2008-10-28 | — | — | US | disclosed |
| WO-2006103342-A9 | INDANYL-PIPERAZINE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SERVIER LAB (FR) | 2007-10-25 | — | — | WO | disclosed |
| EP-1707564-B1 | Indanyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2007-09-12 | — | — | EP | disclosed |
| US-20060223830-A1 | Indanyl-piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2006-10-05 | — | — | US | disclosed |
| WO-2006103342-A2 | INDANYL-PIPERAZINE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2006-10-05 | — | — | WO | disclosed |
| EP-1707564-A2 | Indanyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2006-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223830-A1 | Indanyl-piperazine compounds | HTR4, NR4A1, NR4A3 | TACR1 67/4885CACNA1F 2594/4885CACNA1D 2287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.